Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab

Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer

(2012) Simon Rieder et al.   Anti-Cancer Agents in Medicinal Chemistry

Clinical Biomarkers in Oncology

(2012) Wendy De Roock et al.   Molecular Diagnosis & Therapy

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

(2011) F. Atzori et al.   CLINICAL CANCER RESEARCH

Targeting of Insulin-Like Growth Factor Type 1 Receptor in Ewing Sarcoma: Unfulfilled Promise or a Promising Beginning?

(2011) Alan L. Ho et al.   JOURNAL OF CLINICAL ONCOLOGY

AMG 479, a Novel IGF-1-R Antibody, Inhibits Endometrial Cancer Cell Proliferation Through Disruption of the PI3K/Akt and MAPK Pathways

(2011) Albert Mendivil et al.   Reproductive Sciences

Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL

(2011) Bodvael Pennarun et al.   CELLULAR ONCOLOGY

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

(2010) L R Molife et al.   BRITISH JOURNAL OF CANCER

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

(2010) Paula J. Kaplan-Lefko et al.   CANCER BIOLOGY & THERAPY

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

(2010) T. Doi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Biomarker-Driven Early Clinical Trials in Oncology

(2010) Daniel S. W. Tan et al.   CANCER JOURNAL

Death Receptor Agonists as a Targeted Therapy for Cancer

(2010) J. Wiezorek et al.   CLINICAL CANCER RESEARCH

The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models

(2010) S. A. Flanigan et al.   CLINICAL CANCER RESEARCH

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

(2010) R. S. Herbst et al.   CLINICAL CANCER RESEARCH

The Insulin-like Growth Factor Signaling Pathway as a Target for Treatment of Colorectal Carcinoma

(2010) Gideon P. Ewing et al.   Clinical Colorectal Cancer

Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling

(2010) Stephen J. Zoog et al.   CYTOMETRY PART A

Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma

(2010) Christine H. Chung et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer

(2010) Marie-Claude Beauchamp et al.   Journal of Oncology

Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase

(2009) P. Sabbatini et al.   CLINICAL CANCER RESEARCH

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

(2009) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

(2009) David Olmos et al.   LANCET ONCOLOGY

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

(2009) P. J. Beltran et al.   MOLECULAR CANCER THERAPEUTICS

To kill a tumor cell: the potential of proapoptotic receptor agonists

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL INVESTIGATION

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials

(2008) J. Rodon et al.   MOLECULAR CANCER THERAPEUTICS

IGF1 Promotes Resistance to Apoptosis in Melanoma Cells through an Increased Expression of BCL2, BCL-X(L), and Survivin

(2007) Caroline Hilmi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY